Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia

Renee C. Tschumper, Tait D. Shanafelt, Neil Elliot Kay, Diane F Jelinek

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Predicting disease progression in chronic lymphocytic leukemia (CLL) remains challenging particularly in patients with Rai Stage 0/I disease that have an unmutated immunoglobulin heavy chain variable region (UM IGHV). Even though patients with UM IGHV have a poor prognosis and generally require earlier treatment, not all UM IGHV patients experience more rapid disease progression with some remaining treatment free for many years. This observation suggests biologic characteristics other than known prognostic factors influence disease progression. Alterations in long non-coding RNA (lncRNA) expression levels have been implicated in diagnosis and prognosis of various cancers, however, their role in disease progression of early Rai stage UM CLL is unknown. Here we use microarray analysis to compare lncRNA and mRNA profiles of Rai 0/I UM IGHV patients who progressed in <2 years relative to patients who had not progressed for >5 years. Over 1,300 lncRNAs and 940 mRNAs were differentially expressed (fold change ≥ 2.0; p-value ≤ 0.05). of interest, the differentially expressed lncRNAs T204050, NR_002947, and uc.436+, have known associated genes that have been linked to CLL. Thus, our study reveals differentially expressed lncRNAs in progressive early stage CLL requiring therapy versus indolent early Rai stage UM CLL. These lncRNAs have the potential to impact relevant biological processes and pathways that influence clinical outcome in CLL.

Original languageEnglish (US)
Pages (from-to)60-75
Number of pages16
JournalOncotarget
Volume10
Issue number1
StatePublished - Jan 1 2019

Fingerprint

Long Noncoding RNA
B-Cell Chronic Lymphocytic Leukemia
Disease Progression
Immunoglobulin Heavy Chains
Biological Phenomena
Messenger RNA
Critical Pathways
Microarray Analysis
Therapeutics
Genes

Keywords

  • Chronic lymphocytic leukemia
  • Long non-coding RNA
  • Unmutated immunoglobulin heavy chain variable region

ASJC Scopus subject areas

  • Oncology

Cite this

Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia. / Tschumper, Renee C.; Shanafelt, Tait D.; Kay, Neil Elliot; Jelinek, Diane F.

In: Oncotarget, Vol. 10, No. 1, 01.01.2019, p. 60-75.

Research output: Contribution to journalArticle

@article{d968efabe7e14fd3bd4faa07b33c3ca0,
title = "Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia",
abstract = "Predicting disease progression in chronic lymphocytic leukemia (CLL) remains challenging particularly in patients with Rai Stage 0/I disease that have an unmutated immunoglobulin heavy chain variable region (UM IGHV). Even though patients with UM IGHV have a poor prognosis and generally require earlier treatment, not all UM IGHV patients experience more rapid disease progression with some remaining treatment free for many years. This observation suggests biologic characteristics other than known prognostic factors influence disease progression. Alterations in long non-coding RNA (lncRNA) expression levels have been implicated in diagnosis and prognosis of various cancers, however, their role in disease progression of early Rai stage UM CLL is unknown. Here we use microarray analysis to compare lncRNA and mRNA profiles of Rai 0/I UM IGHV patients who progressed in <2 years relative to patients who had not progressed for >5 years. Over 1,300 lncRNAs and 940 mRNAs were differentially expressed (fold change ≥ 2.0; p-value ≤ 0.05). of interest, the differentially expressed lncRNAs T204050, NR_002947, and uc.436+, have known associated genes that have been linked to CLL. Thus, our study reveals differentially expressed lncRNAs in progressive early stage CLL requiring therapy versus indolent early Rai stage UM CLL. These lncRNAs have the potential to impact relevant biological processes and pathways that influence clinical outcome in CLL.",
keywords = "Chronic lymphocytic leukemia, Long non-coding RNA, Unmutated immunoglobulin heavy chain variable region",
author = "Tschumper, {Renee C.} and Shanafelt, {Tait D.} and Kay, {Neil Elliot} and Jelinek, {Diane F}",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "10",
pages = "60--75",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "1",

}

TY - JOUR

T1 - Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia

AU - Tschumper, Renee C.

AU - Shanafelt, Tait D.

AU - Kay, Neil Elliot

AU - Jelinek, Diane F

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Predicting disease progression in chronic lymphocytic leukemia (CLL) remains challenging particularly in patients with Rai Stage 0/I disease that have an unmutated immunoglobulin heavy chain variable region (UM IGHV). Even though patients with UM IGHV have a poor prognosis and generally require earlier treatment, not all UM IGHV patients experience more rapid disease progression with some remaining treatment free for many years. This observation suggests biologic characteristics other than known prognostic factors influence disease progression. Alterations in long non-coding RNA (lncRNA) expression levels have been implicated in diagnosis and prognosis of various cancers, however, their role in disease progression of early Rai stage UM CLL is unknown. Here we use microarray analysis to compare lncRNA and mRNA profiles of Rai 0/I UM IGHV patients who progressed in <2 years relative to patients who had not progressed for >5 years. Over 1,300 lncRNAs and 940 mRNAs were differentially expressed (fold change ≥ 2.0; p-value ≤ 0.05). of interest, the differentially expressed lncRNAs T204050, NR_002947, and uc.436+, have known associated genes that have been linked to CLL. Thus, our study reveals differentially expressed lncRNAs in progressive early stage CLL requiring therapy versus indolent early Rai stage UM CLL. These lncRNAs have the potential to impact relevant biological processes and pathways that influence clinical outcome in CLL.

AB - Predicting disease progression in chronic lymphocytic leukemia (CLL) remains challenging particularly in patients with Rai Stage 0/I disease that have an unmutated immunoglobulin heavy chain variable region (UM IGHV). Even though patients with UM IGHV have a poor prognosis and generally require earlier treatment, not all UM IGHV patients experience more rapid disease progression with some remaining treatment free for many years. This observation suggests biologic characteristics other than known prognostic factors influence disease progression. Alterations in long non-coding RNA (lncRNA) expression levels have been implicated in diagnosis and prognosis of various cancers, however, their role in disease progression of early Rai stage UM CLL is unknown. Here we use microarray analysis to compare lncRNA and mRNA profiles of Rai 0/I UM IGHV patients who progressed in <2 years relative to patients who had not progressed for >5 years. Over 1,300 lncRNAs and 940 mRNAs were differentially expressed (fold change ≥ 2.0; p-value ≤ 0.05). of interest, the differentially expressed lncRNAs T204050, NR_002947, and uc.436+, have known associated genes that have been linked to CLL. Thus, our study reveals differentially expressed lncRNAs in progressive early stage CLL requiring therapy versus indolent early Rai stage UM CLL. These lncRNAs have the potential to impact relevant biological processes and pathways that influence clinical outcome in CLL.

KW - Chronic lymphocytic leukemia

KW - Long non-coding RNA

KW - Unmutated immunoglobulin heavy chain variable region

UR - http://www.scopus.com/inward/record.url?scp=85059526043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059526043&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 60

EP - 75

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 1

ER -